SG Americas Securities LLC Has $938,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

SG Americas Securities LLC trimmed its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 84.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,710 shares of the company's stock after selling 114,797 shares during the quarter. SG Americas Securities LLC's holdings in Scholar Rock were worth $938,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. FMR LLC grew its holdings in shares of Scholar Rock by 3.1% during the 3rd quarter. FMR LLC now owns 10,196,046 shares of the company's stock worth $81,670,000 after purchasing an additional 308,813 shares in the last quarter. Geode Capital Management LLC boosted its stake in Scholar Rock by 8.5% during the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock worth $12,361,000 after buying an additional 120,489 shares in the last quarter. Millennium Management LLC increased its holdings in Scholar Rock by 159.2% in the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company's stock valued at $7,710,000 after buying an additional 568,512 shares during the period. abrdn plc raised its stake in shares of Scholar Rock by 28.2% in the 3rd quarter. abrdn plc now owns 748,489 shares of the company's stock valued at $5,995,000 after buying an additional 164,715 shares in the last quarter. Finally, Clearbridge Investments LLC acquired a new position in shares of Scholar Rock in the 2nd quarter valued at $6,223,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Price Performance

Shares of Scholar Rock stock traded down $0.02 during trading on Friday, reaching $40.38. The company's stock had a trading volume of 1,580,616 shares, compared to its average volume of 899,168. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The stock has a 50-day moving average price of $42.42 and a two-hundred day moving average price of $25.40. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $3.78 billion, a P/E ratio of -17.18 and a beta of 0.52.

Insider Transactions at Scholar Rock

In other news, General Counsel Junlin Ho sold 9,039 shares of the firm's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $44.20, for a total value of $399,523.80. Following the transaction, the general counsel now owns 195,037 shares of the company's stock, valued at approximately $8,620,635.40. This trade represents a 4.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Public Equities L.P. Invus sold 409,433 shares of Scholar Rock stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the sale, the insider now owns 10,850,005 shares of the company's stock, valued at approximately $417,616,692.45. This represents a 3.64 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 458,974 shares of company stock worth $17,948,788. Corporate insiders own 19.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SRRK shares. Wedbush reissued an "outperform" rating and issued a $47.00 target price on shares of Scholar Rock in a research note on Wednesday. HC Wainwright increased their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Truist Financial raised their target price on Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. JPMorgan Chase & Co. upped their price target on Scholar Rock from $18.00 to $31.00 and gave the company an "overweight" rating in a research report on Monday, October 14th. Finally, Piper Sandler lifted their price objective on Scholar Rock from $28.00 to $42.00 and gave the company an "overweight" rating in a report on Tuesday, October 15th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Scholar Rock presently has an average rating of "Buy" and a consensus target price of $40.43.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.